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Laboratory variable
Prior to
carﬁlzomib
After
carﬁlzomib References
White blood cells 8.2 K/ml 9.3 K/ml 3.9–11.0 K/ml
Hb 8.8 g/dl 9.1 g/dl 12.7–18.0 g/dl
Platelets 100 K/ml 122 K/ml 160–392 K/ml
Haptoglobin 150 mg/dl 151 mg/dl 40–290 mg/dl
Lactate dehydrogenase Unavailable 144 IU/liter 100–250 IU/liter
Sodium 137 mEq/l 131 mEq/l 138–145 mEq/l
Potassium 4.1 mEq/l 6.3 mEq/l 3.7–5.2 mEq/l
Creatinine 0.8 mg/dl 3.4 mg/dl 0.6–1.2 mg/dl
Calcium 8.0 mg/dl 8.6 mg/dl 8.6–10.3 mg/dl
Albumin 3.2 g/dl 3.9 g/dl 3.5–4.8 g/dl
Urine protein/creatinine ratio Unavailable 3 g/g <0.2 g/g
Urine albumin/creatinine ratio Unavailable 0.14 g/g <0.03 g/g
Serum k light chains 3.96 mg/l 5.55 mg/l 1.35–24.19 mg/l
Serum l light chains 1880 mg/l 3630 mg/l 0.24–6.66 mg/l
Serum k/l light chain ratio 0.002 0.0015 0.26–1.65
Urine k light chains Unavailable 13.50 mg/l 1.35–24.19 mg/l
Urine l light chains Unavailable 8190.00 mg/l 0.24–6.66 mg/l
Urine k/l ratio Unavailable 0.0016 2.04–10.37
Urine sodium Unavailable 49 mEq/l
Urine potassium Unavailable 32 mEq/l
Urine chloride Unavailable 41 mEq/l
Urine osmolarity Unavailable 352 mOsm/l
Urine creatinine Unavailable 49.8 mg/dl
Fractional excretion of sodium Unavailable 2.55%
Urinalysis
pH 7.0 6.0 5.0–8.0
Speciﬁc gravity 1.011 1.008 1.002–1.035
Protein Negative 1þ Negative
Blood 1þ 2þ Negative
Red blood cell number 0/hpf 63/hpf <3/hpf
White blood cell number 0/hpf 2/hpf <3/hpf
hpf, high-power ﬁeld.INTRODUCTION
C arﬁlzomib is a selective proteasome inhibitorapproved in 2012 for the treatment of relapsed and
refractory multiple myeloma. It was developed with the
aim of achieving improved safety proﬁle and greater
efﬁcacy in patients who failed conventional treatments.
A phase II trial for single-agent carﬁlzomib analyzed
safety data in 526 treated patients and reported a rise
in serum creatinine in 127 (24.1%) patients.1 In 73.2%
of these 127 patients, the rise in serum creatinine was
attributed to the carﬁlzomib with no other precipitating
event identiﬁed.1 These data suggest that carﬁlzomib
may be a cause of acute kidney injury (AKI), although
the mechanism has not been determined. There have
been several case reports providing evidence of AKI sec-
ondary to carﬁlzomib.2–7 Two recent reports describe
thrombotic microangiopathy associated with carﬁlzo-
mib administration, although causality was not deﬁni-
tively established.4,5 To our knowledge this is the ﬁrst
case report of biopsy-proven acute tubular necrosis
(ATN) in a patient with multiple myeloma who was
treated with carﬁlzomib.
CASE PRESENTATION
A 60-year-old man with IgG-l multiple myeloma who
had received autologous stem cell transplantation 2 years
prior and suffered a recent relapse presented to the
hospital with shortness of breath and chest discomfort.
Past medical history was also notable for atrial ﬁbrilla-
tion and congestive heart failure with preserved
ejection fraction. In the emergency department he
appeared to be in mild distress with blood pressure of
141/74 mm Hg, heart rate 83 bpm, respirations 16 per
minute, and an oxygen saturation of 97% on room air.
Physical examination revealed clear lungs, normal S1
and S2 without murmur, and pitting edema of both legs.International Reports (2016) 1, 89–92Electrocardiogram revealed normal sinus rhythm with
peaked T waves in the anterior leads with right bundle
branch block. Laboratory data, which are summarized in
Table 1, were signiﬁcant for serum sodium of 131 mmol/l,
potassium of 6.3 mmol/l, and creatinine of 3.4 mg/dl.89
Figure 1. The major ﬁnding was diffuse acute tubular injury
affecting both proximal and distal tubules with epithelial simpliﬁ-
cation, luminal ectasia, attenuation of brush border, coarse clear
cytoplasmic vacuolization, and focal shedding of degenerating
epithelial cells into the lumen. These degenerative tubular changes
were present in tubules lacking myeloma-type casts (hematoxylin
and eosin, original magniﬁcation X400).
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light chains were 3630 mg/l (ratio 0.0015). Twenty days
earlier, the patient had a baseline serum creatinine of 0.8
mg/dl, a serum free l light chain level of 1800mg/l, and a
serum free k light chain level of 3.96 mg/l (ratio 0.0022).
Notably, the patient was given 2 consecutive injections
of carﬁlzomib with decadron at a dose of 20 mg/m2 7
days prior to presentation. He denied nonsteroidal anti-
inﬂammatory drug use, radiocontrast exposure, or any
other changes in medications. His outpatient medica-
tions included acyclovir, warfarin, fentanyl patch,
furosemide, gabapentin, digoxin, metoprolol, olanza-
pine, ramipril, potassium chloride, bupropion, and
alprazolam. A urine sample obtained by bladder
catheterization revealed pH 6.0, speciﬁc gravity 1.008,
1þ protein, 2þ blood, and 2white blood cells and 63 red
blood cells per high-power ﬁeld. The spot urine protein/
creatinine ratio was 3 g/g, and the albumin/creatinine
ratio was 0.14 g/g. Urine k light chains were 13.5 mg/l,
and urine l light chains were 8190.0 mg/l, yielding a
urine k/l ratio of 0.0016. Renal ultrasound revealed no
hydronephrosis and normal kidney size (right kidney
12.8 cm and left kidney 12 cm). Several days later the
creatinine stabilized at 2.6 mg/dl, at which point a
kidney biopsy was performed.
Renal Biopsy Findings
The 7 glomeruli sampled for light microscopy were
unremarkable. The major histologic ﬁnding was
diffuse acute tubular injury involving 100% of the
cortical parenchyma, affecting both proximal and
distal tubules, associated with mild interstitial edema
and sparse interstitial inﬂammation. The cortical tu-
bules exhibited luminal ectasia, attenuation of brush
border, focal coarse clear cytoplasmic vacuolization,
and enlarged reparative nuclei containing nucleoli
(Figure 1). A minority of distal tubules contained
atypical hard crystalline casts of the myeloma type
with giant cell reaction (Figure 2). By immunoﬂuo-
rescence microscopy, the casts revealed restricted 3þ
staining for l light chain, with negative staining for k
light chain. Congo red stain for amyloid was negative.
The presence of diffuse acute tubular injury out of
proportion to the sparse crystalline casts suggested
ischemic or toxic ATN superimposed on mild myeloma
cast nephropathy. The close temporal association with
the initiation of carﬁlzomib and the absence of other
obvious recent insults suggested that the medication
had a role in development of the severe acute tubular
injury.
The patient’s light-chain burden continued to in-
crease, and he was treated with cyclophosphamide. His
kidney function progressively worsened and he even-
tually required renal replacement therapy.90DISCUSSION
Carﬁlzomib is a relatively new agent approved for the
treatment of relapsed and refractory multiple myeloma.
It has been associated with AKI as an adverse event in a
phase II trial.1 Most of the cases of AKI in this phase II
trial were attributed to carﬁlzomib, as no other
precipitating cause could be identiﬁed; however, the
mechanism of AKI was not determined. There have also
been a number of case reports2–7 attributing AKI to
carﬁlzomib, some suggesting that thrombotic micro-
angiopathy may have been the mechanism of injury
based on clinical presentation and evidence from kid-
ney biopsies, but deﬁnitive causality was not
established.4,5
It can be difﬁcult to determine the mechanism of
AKI in patients with multiple myeloma because the
differential is typically broad and includes a prerenal
state from nausea and vomiting, hypercalcemia leading
to renal vasoconstriction, monoclonal Ig deposition
disease, myeloma cast nephropathy, infections, and
drug-induced toxicity, among others (Table 2). A pre-
renal state was unlikely in our patient because he did
not present with clinical signs of volume depletion, he
had no vomiting, diarrhea, or hypercalcemia, and his
fractional excretion of sodium was >2% approximately
24 hours after he last received furosemide. He pre-
sented with a rise in serum l light chains and markedly
reduced k/l ratio that can be explained by both
worsening myeloma with increased production of
light chains and decreased excretion due to kidney
failure. Several case reports in the literature haveKidney International Reports (2016) 1, 89–92
Table 2. Teaching points
Acute kidney injury in patients with multiple myeloma has many potential etiologies,
including direct consequences of the hematologic malignancy and nephrotoxicity
of therapeutic agents.
Carﬁlzomib has been associated with acute kidney injury, but few patients have been
subjected to diagnostic kidney biopsy.
The patient presented here, who had multiple myeloma for years, developed acute
tubular necrosis and mild myeloma cast nephropathy 1 week following exposure
to carﬁlzomib.
It is plausible that carﬁlzomib may promote acute tubular necrosis by direct cellular
toxicity, possibly exacerbated by the toxic effects of monoclonal light chains.
Figure 2. The biopsy contained several atypical casts surrounded by
multinucleated giant cells and dehisced tubular epithelial cells,
typical of myeloma casts (hematoxylin and eosin, original magniﬁ-
cation X600).
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thrombotic microangiopathy.4,5,7 However, our patient
had no clinical manifestations of thrombotic micro-
angiopathy, such as hemolytic anemia, thrombocyto-
penia, or schistocytes, and no histologic evidence of
thrombosis. There was no evidence on kidney biopsy
of acute interstitial nephritis, which has been described
in a single patient treated with bortezomib, a similar
proteasome inhibitor.8
The patient presented herein suffered AKI 1 week
after receiving 2 consecutive doses of carﬁlzomib. In
the phase II trial,1 the incidence of ﬁrst episodes of
worsening renal function was evenly distributed across
earlier and later time points, suggesting that a high
cumulative exposure is not required for development
of toxic AKI.1 The renal biopsy revealed ATN. While
the renal biopsy also showed mild focal myeloma cast
nephropathy, the degree of acute tubular injury
appeared far out of proportion to the few myeloma
casts. To our knowledge this is the ﬁrst case report of
biopsy-proven ATN in a patient with multiple
myeloma treated with carﬁlzomib.
Although not previously demonstrated, it is plau-
sible that carﬁlzomib could cause ATN by its cellular
effects on renal tubular epithelium. Carﬁlzomib is a
selective proteasome inhibitor similar to bortezomib.
Both drugs target the ubiquitin–proteasome system
and inhibit the 20s proteasome. The ubiquitin–pro-
teasome system is an intracellular degradation pathway
in eukaryotic cells that normally leads to degradation
of proteins such as p53 and nuclear factor-kB, which
are involved in apoptosis, inﬂammation, senescence,
and angiogenesis.9 Normal function of the 20s pro-
teasomal system is critical to cellular maintenance and
survival pathways. Inhibition of the 20s proteasomeKidney International Reports (2016) 1, 89–92system, by reducing the degradation of proteins such
as p53, could enhance apoptosis. While this is a
desirable result for malignant cells, proteasome inhi-
bition could exert harmful effects in renal tubular
epithelial cells and potentially other cell types, result-
ing in AKI. In a murine model of ischemia–reperfusion
injury, mice receiving the 20s proteasome inhibitor
bortezomib experienced a signiﬁcant increase in
tubular cell apoptosis and greater decline in kidney
function compared to control mice subjected to
ischemia–reperfusion injury alone.9 Bortezomib and
carﬁlzomib have similar mechanisms of action. How-
ever, acute kidney injury is less frequently reported
following exposure to bortezomib as compared to
carﬁlzomib. One explanation could be that carﬁlzomib
is used in refractory or relapsed multiple myeloma
where some tubular injury might already have
occurred secondary to monoclonal light chains, thereby
predisposing to further tubular injury by the drug.
While carﬁlzomib may have been the etiologic factor
causing ATN, we must also consider that the ATN
could result from a combined effect of the drug and
monoclonal light chains. Excessive production of
monoclonal light chains may be directly toxic to
tubular epithelial cells.10 For example, in an in vitro
study, exposure to l light chains induced a 6-fold in-
crease in the number of apoptotic cultured human
proximal tubule cells.10 Monoclonal light chains have
been shown to generate intracellular oxidative stress in
the form of hydrogen peroxide, which in turn pro-
motes synthesis of chemokines and cytokines that lead
to inﬂammation.11 In particular, monoclonal light
chains activate apoptosis signal–regulating kinase 1,
which is a key mediator of oxidative stress–induced
apoptosis.11
Given the potential for tubular toxicity from light
chains, one must consider at least 2 additional
possible mechanisms for ATN in this clinical setting.
First, it is plausible that our patient suffered light
chain–induced tubular injury that was then com-
pounded by the “second hit” of carﬁlzomib, with the
combined insult being sufﬁcient to cause ATN. Sec-
ond, it is plausible that the carﬁlzomib caused acute91
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the ability of the proximal tubules to endocytose and
catabolize the high ﬁltered load of monoclonal light
chains, resulting in the development of cast ne-
phropathy. However, it should be noted that there
was no evidence of light chain proximal tubulopathy,
in which crystalline intracytoplasmic inclusions
develop within proximal tubular cells. Whether
acting alone or in combination with nephrotoxic light
chains, the close temporal relationship between car-
ﬁlzomib therapy and AKI suggests that the drug
played some pathogenetic role in the development
of AKI.
CONCLUSION
To our knowledge this is the ﬁrst report of biopsy-
proven ATN occurring after carﬁlzomib treatment for
multiple myeloma. Although our case demonstrates an
association of carﬁlzomib administration and ATN, an
exact mechanism of injury remains to be determined.
This adverse event could be the result of a combined
cellular effect of the drug itself and nephrotoxicity of
monoclonal light chains. Greater use of renal biopsy in
this setting may provide insight into the prevalence of
ATN in multiple myeloma patients treated with
carﬁlzomib.
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